{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:06:36Z","timestamp":1760385996024,"version":"3.37.3"},"reference-count":23,"publisher":"BMJ","issue":"7","funder":[{"name":"Research and Innovation Framework Programme","award":["643806","PHC-26-2014"],"award-info":[{"award-number":["643806","PHC-26-2014"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2023,12,5]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Intestinal inflammation with contradictory data on faecal calprotectin (fCP) levels is documented in patients with cystic fibrosis (CF). The aim of this study was to longitudinally evaluate fCP in a cohort of children with CF and their relationship with clinical variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective observational study to assess evolution of fCP levels, primary aimed at improving fat absorption. Along 1.5\u2009years of follow-up (November 2016\u2013May 2018) with four study visits pertaining to a pilot study (two of four) and to a clinical trial (two of four), the study outcomes were measured.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Six European CF centres in the context of MyCyFAPP Project.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects<\/jats:title><jats:p>Children with CF and pancreatic insufficiency (2\u201318 years old).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measurements<\/jats:title><jats:p>fCP levels, pulmonary function (percentage of forced expiratory volume in 1 s (FEV<jats:sub>1<\/jats:sub>%)) and coefficient of fat absorption (CFA). Additionally, in the last two visits, gastrointestinal (GI) symptoms were evaluated through the PedsQL-GI Questionnaire. Linear mixed regression models were applied to assess association between fCP and FEV<jats:sub>1<\/jats:sub>, CFA and GI symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-nine children with CF and pancreatic insufficiency were included. fCP levels were inversely associated with total modified specific PedsQL-GI score (p=0.04) and positively associated with diarrhoea (p=0.03), but not with CFA. Along the four study visits, fCP significantly increased (from 62 to 256\u2009\u00b5g\/g) and pulmonary function decreased (from 97% to 87%), with a significant inverse association between the two study outcomes (p&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In children with CF, fCP levels are inversely associated with pulmonary function and thus the specificity of fCP as a marker of intestinal inflammation in paediatric patients with CF warrants further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2023-326221","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:25:14Z","timestamp":1702923914000},"page":"552-556","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term evaluation of faecal calprotectin levels in a European cohort of children with cystic fibrosis"],"prefix":"10.1136","volume":"109","author":[{"given":"Maria","family":"Roca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etna","family":"Masip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Boon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie M","family":"Hulst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Garriga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A E","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bulfamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"de Boeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ribes-Koninckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-0652","authenticated-orcid":false,"given":"Joaquim","family":"Calvo-Lerma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"2024122800050526000_109.7.552.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2024122800050526000_109.7.552.2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ajcn\/69.1.127","article-title":"Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids","volume":"69","author":"Kalivianakis","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2024122800050526000_109.7.552.3","article-title":"Pancreatic enzyme replacement therapy for people with cystic fibrosis","volume":"8","author":"Somaraju","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2024122800050526000_109.7.552.4","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20286"},{"key":"2024122800050526000_109.7.552.5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MPA.0000000000002016","article-title":"Coefficient of fat absorption to measure the efficacy of pancreatic enzyme replacement therapy in people with cystic fibrosis: gold standard or coal standard?","volume":"51","author":"Borowitz","year":"2022","journal-title":"Pancreas"},{"key":"2024122800050526000_109.7.552.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014931","article-title":"Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP)","volume":"7","author":"Calvo-Lerma","year":"2017","journal-title":"BMJ Open"},{"key":"2024122800050526000_109.7.552.7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jcf.2020.04.001","article-title":"Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with cystic fibrosis","volume":"19","author":"Boon","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024122800050526000_109.7.552.8","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jcf.2020.11.016","article-title":"Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis","volume":"20","author":"Calvo-Lerma","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024122800050526000_109.7.552.9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MPG.0000000000003046","article-title":"The use of fecal calprotectin testing in paediatric disorders: a position paper of the European society for paediatric gastroenterology and nutrition gastroenterology committee","volume":"72","author":"Koninckx","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024122800050526000_109.7.552.10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2431-14-133","article-title":"Calprotectin in cystic fibrosis","volume":"14","author":"Rumman","year":"2014","journal-title":"BMC Pediatr"},{"key":"2024122800050526000_109.7.552.11","doi-asserted-by":"crossref","first-page":"109198","DOI":"10.1016\/j.foodres.2020.109198","article-title":"Lessons learnt from MyCyFAPP project: effect of cystic fibrosis factors and inherent-to-food properties on lipid digestion in foods","volume":"133","author":"Calvo-Lerma","year":"2020","journal-title":"Food Res Int"},{"key":"2024122800050526000_109.7.552.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213216","article-title":"Clinical validation of an evidence-based method to adjust pancreatic enzyme replacement therapy through a prospective Interventional study in paediatric patients with cystic fibrosis","volume":"14","author":"Calvo-Lerma","year":"2019","journal-title":"PLoS One"},{"key":"2024122800050526000_109.7.552.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225004","article-title":"Assessing gastro-intestinal related quality of life in cystic fibrosis: validation of PedsQL GI in children and their parents","volume":"14","author":"Boon","year":"2019","journal-title":"PLoS One"},{"key":"2024122800050526000_109.7.552.14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MPG.0000000000001542","article-title":"Fecal calprotectin and eosinophil-derived neurotoxin in healthy children between 0 and 12 years","volume":"65","author":"Roca","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024122800050526000_109.7.552.15","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000178439.64675.8d"},{"key":"2024122800050526000_109.7.552.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77625-7","article-title":"Fecal calprotectin in healthy children aged 4-16 years","volume":"10","author":"Roca","year":"2020","journal-title":"Sci Rep"},{"key":"2024122800050526000_109.7.552.17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jcf.2017.03.010","article-title":"Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children","volume":"16","author":"Garg","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024122800050526000_109.7.552.18","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000683"},{"key":"2024122800050526000_109.7.552.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198457","article-title":"Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis","volume":"13","author":"de Freitas","year":"2018","journal-title":"PLoS One"},{"key":"2024122800050526000_109.7.552.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087796","article-title":"Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: a randomised clinical trial","volume":"9","author":"Bruzzese","year":"2014","journal-title":"PLoS One"},{"key":"2024122800050526000_109.7.552.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138062","article-title":"Evidence for a cystic fibrosis enteropathy","volume":"10","author":"Adriaanse","year":"2015","journal-title":"PLoS One"},{"key":"2024122800050526000_109.7.552.22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MPG.0000000000001544","article-title":"Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years","volume":"65","author":"Ellemunter","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024122800050526000_109.7.552.23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124080","article-title":"Increased fecal calprotectin is associated with worse gastrointestinal symptoms and quality of life scores in children with cystic fibrosis","volume":"9","author":"Beaufils","year":"2020","journal-title":"J Clin Med"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2023-326221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:06:51Z","timestamp":1735373211000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2023-326221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,6,19]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/archdischild-2023-326221"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2023-326221","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"type":"print","value":"0003-9888"},{"type":"electronic","value":"1468-2044"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}